The term "Treatment-Emergent" is not popular among those who promote heavy-duty treatments.
17 years ago, when I read study papers describing the androgen receptor [AR] as 'wild type' at diagnosis, & reporting on the common AR alterations after ADT failure, I realized that I had to delay Lupron initiation as long as possible. After all, ADT is never offered with curative intent. Why do many feel they must "hit it hard" with ADT, sooner rather than later, when the treatment is merely palliative? The downside is rarely discussed.
"Treatment-emergent neuroendocrine prostate cancer (T-NEPC) mainly occurs in the advanced castration-resistant prostate cancer (CRPC), which is caused by the transformation of ordinary prostate adenocarcinoma after androgen-deprivation therapy (ADT). The main clinical manifestations of T-NEPC include low PSA level, high tumor metastasis load, and rapid resistance to ADT. T-NEPC is an aggressive variant of CRPC, with a poor prognosis. Most T-NEPC patients die within 1 to 2 years after diagnosis, accounting for approximately 25% of CRPC deaths."
It may well be my fate, but I have tried my best to avoid it.
{Victorian fairground expression: "What you gain on the roundabouts you lose on the swings?"}
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.